Literature DB >> 26812225

Association between Hepatic Triglyceride Content and Left Ventricular Diastolic Function in a Population-based Cohort: The Netherlands Epidemiology of Obesity Study.

Ralph L Widya1, Renée de Mutsert1, Martin den Heijer1, Saskia le Cessie1, Frits R Rosendaal1, J Wouter Jukema1, Johannes W A Smit1, Albert de Roos1, Hildo J Lamb1.   

Abstract

PURPOSE: To investigate the association between hepatic triglyceride content and left ventricular (LV) diastolic function while taking potential confounding factors into account, including the components of the metabolic syndrome.
MATERIALS AND METHODS: The study was approved by the institutional review board, and all participants gave informed consent. In this cross-sectional analysis of baseline data from the Netherlands Epidemiology of Obesity study, a population-based, prospective cohort study, participants (45% men; mean age ± standard deviation, 55.3 years ± 6.2) underwent magnetic resonance (MR) spectroscopy and MR imaging to assess hepatic triglyceride content and LV diastolic heart function (ratio of peak filling rates of the early filling phase and atrial contraction [E/A ratio]). Multivariate linear regression analysis was performed while adjusting for confounding factors, and results were additionally stratified according to body mass index.
RESULTS: Adjustment for age, sex, heart rate, alcohol consumption, pack-years of smoking, all components of the metabolic syndrome, and visceral adiposity attenuated crude observed associations. A 10-fold increase in hepatic triglyceride content was associated with a change in mean E/A ratio of -0.004 (95% confidence interval [CI]: -0.134, 0.125) in the total study population, -0.194 (95% CI: -0.430, 0.042) in the normal-weight subgroup, 0.079 (95% CI: -0.090, 0.248) in the overweight subgroup, and -0.109 (95% CI: -0.186, -0.032) in the obese subgroup.
CONCLUSION: Fatty liver itself could, at least in obesity, pose a risk of myocardial dysfunction above and beyond known cardiovascular risk factors that are clustered within the metabolic syndrome. The association in the obese subgroup was small, and future studies with larger samples sizes are required to investigate to what extent the association exists and differs in normal-weight, overweight, and obese persons to unravel its clinical relevance. (©) RSNA, 2016 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26812225     DOI: 10.1148/radiol.2015150035

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  5 in total

1.  Left ventricular diastolic function worsens over time in the setting of myocardial steatosis.

Authors:  Paulo Magno Martins Dourado
Journal:  Int J Cardiovasc Imaging       Date:  2022-02-18       Impact factor: 2.357

2.  Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction.

Authors:  Alexandria Miller; Jennifer McNamara; Scott L Hummel; Matthew C Konerman; Monica A Tincopa
Journal:  Sci Rep       Date:  2020-07-24       Impact factor: 4.379

3.  Associations of sleep duration and quality with serum and hepatic lipids: The Netherlands Epidemiology of Obesity Study.

Authors:  Maxime M Bos; Raymond Noordam; Rosa van den Berg; Renée de Mutsert; Frits R Rosendaal; Gerard Jan Blauw; Patrick C N Rensen; Nienke R Biermasz; Diana van Heemst
Journal:  J Sleep Res       Date:  2018-10-15       Impact factor: 3.981

4.  SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob-/- mice.

Authors:  Damilola D Adingupu; Sven O Göpel; Julia Grönros; Margareta Behrendt; Matus Sotak; Tasso Miliotis; Ulrika Dahlqvist; Li-Ming Gan; Ann-Cathrine Jönsson-Rylander
Journal:  Cardiovasc Diabetol       Date:  2019-02-07       Impact factor: 9.951

5.  The association of non-alcoholic fatty liver disease and cardiac structure and function-Framingham Heart Study.

Authors:  Laura S Chiu; Alison Pedley; Joseph M Massaro; Emelia J Benjamin; Gary F Mitchell; David D McManus; Jayashri Aragam; Ramachandran S Vasan; Susan Cheng; Michelle T Long
Journal:  Liver Int       Date:  2020-07-25       Impact factor: 5.828

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.